GNRH1 and stroke disorder: In the phase III HERO trial, which included 934 patients treated with GnRH agonist leuprolide or GnRH antagonist relugolix, this last one was associated with a 54% lower risk of nonfatal myocardial infarction, nonfatal stroke and all-cause mortality [62].